PKU GOLIKE PLUS 16+ – acceptability and tolerance market research study

Applied Pharma Research (Switzerland)0 个研究点目标入组 15 人开始时间: 2019年7月10日最近更新: 2022年8月5日

适应症

试验速览

暂无简介。

•1. Male and female patients with a diagnosis of phenylketonuria, aged =16 years
•2. Subjects who are already taking a protein substitute for PKU and are willing to replace at least part of their prescription with the new study product for 7 days
•3. Willing and able to give a written informed consent

•1. Presence of serious concurrent illness
•2. Presence of current illnesses that could interfere with the study (for instance, inflammatory status, etc)
•3. Status of pregnancy or lactation, for females
•4. Likelihood that the patient will not be compliant with the protocol requirements, in the judgement of the Lead Dietitian
•5. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
•6. Use of antibiotics in the week prior to study entry
•7. Use of sapropterin
•8. Patients aged less than 16 years

发起方

Applied Pharma Research (Switzerland)